| Patient | Ernest Hemingway |
|---|---|
| Date of birth | 1970-07-21 |
| Identifiers | MRN HR-ET003-SYN; SSN (made up) 000-03-7419 |
| Document date | 2026-03-16 |
| Author | Walter Brandt-Ochoa, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review, seen the same day by hepatology. [S]
Mr. Hemingway returns two weeks after intake and is seen by Dr. Solheim of hepatology on the same day. The HFE test drawn at intake shows that he is homozygous for C282Y. He has taken naltrexone 50 mg daily; he had mild nausea for three days, which passed. By his diary he has cut down from about ten drinks a day to five or six, with none before evening on most days. He has had no tremor, sweats or trouble sleeping beyond his usual. He has taken sertraline 50 mg daily with loose stools for a few days and no other side effects. His home blood pressure average is 146/90 on amlodipine 5 mg. His guns were taken to the locked storage at his shooting club the week after intake, and he keeps no ammunition at home. He has started weekly psychotherapy. His headaches are unchanged, two or three a week. [S]
| Element | Detail |
|---|---|
| HFE genotype | C282Y homozygous |
| Alcohol | Five or six drinks a day, down from about ten; none before evening |
| Naltrexone | 50 mg daily; nausea for three days, now gone |
| Sertraline | 50 mg daily for two weeks; loose stools for a few days |
| Home blood pressure | Average 146/90 |
| Firearms | Stored at his shooting club since last week; no ammunition at home |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; tiredness unchanged |
| Gastrointestinal | Positive | Nausea for three days on starting naltrexone, now gone; no abdominal pain or jaundice |
| Neurological | Positive | Headaches two or three times a week; no tremor |
| Psychiatric | Positive | Mood still low; no thoughts of suicide or wishes to be dead since the last visit |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naltrexone 50 mg oral tablet, one tablet daily, to reduce heavy drinking | One tablet daily | Oral route | 2026-03-02 | active | S |
| Thiamine 100 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-02 to 2026-08-31 | completed | S |
| Sertraline 50 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-02 to 2026-04-13 | completed | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-02 to 2026-06-08 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-16 | Body height | 183 | cm | S |
| 2026-03-16 | Body weight | 97.4 | kg | S |
| 2026-03-16 | Body mass index (BMI) [Ratio] | 29.1 | kg/m2 | S |
| 2026-03-16 | Systolic blood pressure | 144 | mm[Hg] | S |
| 2026-03-16 | Diastolic blood pressure | 90 | mm[Hg] | S |
| 2026-03-16 | Heart rate | 84 | /min | S |
| 2026-03-16 | Respiratory rate | 16 | /min | S |
| 2026-03-16 | Body temperature | 36.7 | Cel | S |
| 2026-03-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-16 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 58 | U/L | 10-40 U/L | High | S |
| 2026-03-16 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 66 | U/L | 7-55 U/L | High | S |
| 2026-03-16 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 160 | U/L | 8-61 U/L | High | S |
| 2026-03-16 | Ferritin [Mass/volume] in Serum or Plasma | 1395 | ng/mL | 24-336 ng/mL | High | S |
| 2026-03-16 | Liver stiffness by US.transient elastography | 9.4 | kPa | Below 7.0 kPa makes significant fibrosis unlikely; 12.5 kPa or more suggests cirrhosis | High | S |
Vital signs recorded on 2026-03-16; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert; no smell of alcohol; blood pressure 144/90, pulse 84; weight 97.4 kg |
| Abdomen | Liver edge palpable 1 cm below the costal margin, smooth and non-tender; no spleen felt; no ascites |
| Skin | No jaundice, spider naevi or palmar erythema; no bronze pigmentation |
| Neurological | No tremor; gait steady |
| Psychiatric | Engaged and direct; mood low |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Alcohol use disorder, severe; heavy daily drinking for most of his adult life; synthetic modern episode linked to his documented heavy drinking | active | confirmed | F10.20 | S — Synthetic modern coding of DSM-5-TR severe alcohol use disorder (seven criteria); person-first language; not a claim about his real diagnosis. |
| Raised transferrin saturation and ferritin found on routine intake tests, cause not yet known (heavy drinking, liver disease or iron overload) | resolved | confirmed | R79.0 | S — Synthetic presenting finding; superseded when HFE testing gave the diagnosis. |
| Hereditary hemochromatosis, HFE C282Y homozygous, with iron overload (ferritin over 1,000 ng/mL) and no advanced liver fibrosis on imaging | active | confirmed | E83.110 | S — Synthetic modern diagnosis. Whether he had hemochromatosis is disputed (CLM-0013); the modern diagnosis is not offered as proof of it. |
| Major depressive disorder, single episode, moderate; Mood Disorder Questionnaire negative and no history of mania or hypomania | active | confirmed | F32.1 | S — Synthetic modern diagnosis; not a claim about his real mood. The roster's bipolar disorder lead is disputed (CLM-0014) and is not used. |
| Essential hypertension, stage 2, with heavy drinking contributing | active | confirmed | I10 | S — Synthetic modern diagnosis confirmed by home readings. |
| Post-concussion symptoms (headaches, slowed thinking and forgetfulness) after repeated head injuries, most recently a concussion with a skull fracture a year ago; chronic traumatic encephalopathy is not diagnosed | active | confirmed | F07.81 | S — Synthetic modern diagnosis anchored to his documented head injuries; alcohol and depression also affect the symptoms. |
| Prediabetes (HbA1c 6.1%) | active | confirmed | R73.03 | S — Synthetic finding on diabetes screening; iron overload and alcohol both raise the risk of diabetes. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | HFE genotyping | Once, when transferrin saturation is 45% or more with a raised ferritin | Completed today | C282Y homozygous (result of the intake sample, reported as narrative) |
| Laboratory | Serum ferritin during induction phlebotomy | At diagnosis, then about every 10 to 12 phlebotomies; target 50 to 100 ng/mL | Completed today | Ferritin 1,395 ng/mL before the first phlebotomy |
| Laboratory | Transferrin saturation | At diagnosis and as ferritin nears target | Up to date | 76% at intake |
| Imaging | Liver fibrosis staging (ferritin over 1,000 ng/mL and raised ALT) | Once at diagnosis: elastography, MRI or biopsy | Completed today | Transient elastography 9.4 kPa (indeterminate); controlled attenuation parameter 288 dB/m; MRI with iron quantification and elastography ordered instead of a biopsy |
| Medication safety | Weekly phlebotomy of 500 mL | Weekly during induction | Ordered | First session next week |
| Self-management | Diet: no iron or vitamin C supplements, no raw shellfish | Every visit | Completed today | Explained with a written sheet; he takes no supplements |
| Referral | Testing offered to first-degree relatives | At diagnosis | Completed today | Letter for first-degree relatives given to him; whether to share it is his choice; no relative's result is recorded |
| Laboratory | Liver tests on naltrexone | Baseline, about one month, then every three to six months | Completed today | AST 58, ALT 66 and GGT 160 U/L, falling from 70, 78 and 196 |
| Survey | Drinking quantity and goal (AUDIT-C, drinking diary) | Every visit | Completed today | Diary: five or six drinks a day; AUDIT-C next at the six-week visit |
| Medication safety | Opioid use and pain plan on naltrexone | Every visit | Completed today | No opioids; wallet card explaining naltrexone |
| Examination | Alcohol withdrawal risk and symptoms when cutting down or stopping | Each visit while cutting down | Completed today | No tremor, sweating or tachycardia; reducing gradually |
| Medication safety | Thiamine | Daily while drinking heavily | Completed today | Taking thiamine 100 mg daily |
| Survey | Depression (PHQ-9) | At least monthly during acute treatment | Up to date | PHQ-9 16 two weeks ago; next at the six-week visit |
| Medication safety | Sertraline adherence and side effects | Two weeks after starting or changing the dose, then each visit | Completed today | Two-week review: loose stools for a few days; continue 50 mg |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, firearm storage and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | C-SSRS screen negative since the last visit; firearms stored off-site; safety plan reviewed |
| Self-management | Psychotherapy (CBT) | Weekly | Completed today | First session last week |
| Examination | Blood pressure, home readings, weight and cardiac auscultation | Every visit | Completed today | 144/90 in clinic; home average 146/90; weight 97.4 kg; no murmur |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension | Ordered | Ordered at intake; not yet scheduled |
| Examination | Post-concussion symptoms (headache frequency, sleep, concentration) | Every visit | Completed today | Headaches two or three times a week; sleeping six hours |
| Referral | Hepatology consultation | At diagnosis of iron overload with raised liver tests | Completed today | Seen by Dr. Solheim today |
Goal progress:
Guideline basis: Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases (2011); ACG Clinical Guideline: Hereditary Hemochromatosis (2019); The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, hypertension and depression, bipolar, and mood disorders monographs (2026)
Follow-up: Weekly phlebotomy from next week. MRI of the liver within four weeks. Six-week review in four weeks with blood count, ferritin, liver tests, PHQ-9 and AUDIT-C. Weekly psychotherapy. Next scheduled visit 2026-04-13: six-week review: phlebotomy, drinking, mood, blood pressure and liver imaging. [S]